News & Updates
Filter by Specialty:
Empagliflozin benefits similar between MRA users, nonusers
In patients with heart failure (HF) and preserved ejection fraction, treatment with empagliflozin delivers comparable benefits in reducing first hospitalization for HF or cardiovascular death (primary outcome) between users and nonusers of mineralocorticoid receptor antagonists (MRA), reports a study.
Empagliflozin benefits similar between MRA users, nonusers
31 Mar 2022
Ebbs and flows in weight influence CVD risk in T2D patients
In individuals with type 2 diabetes (T2D), greater variability in adiposity indices (BMI and waist circumference [WC]) was tied to increased risk of cardiovascular disease (CVD) outcomes and death – but an intensive weight loss programme mitigated this risk, a study suggests.
Ebbs and flows in weight influence CVD risk in T2D patients
31 Mar 2022
Robotic exoskeleton helps with mobilization in patients with heart failure
The use of a robotic exoskeleton is a feasible intervention to assist mobilization in patients with advanced heart failure, according to a recent study.
Robotic exoskeleton helps with mobilization in patients with heart failure
31 Mar 2022
Low-dose aspirin prevents common GI cancers in Chinese adults without ASCVD
Low-dose aspirin reduces risks of some common gastrointestinal (GI) cancers, including colorectal cancer (CRC) and gastric cancer (GC), in Chinese without atherosclerotic cardiovascular disease (ASCVD), compared with paracetamol, the first population-wide study from the University of Hong Kong (HKU) has shown.
Low-dose aspirin prevents common GI cancers in Chinese adults without ASCVD
31 Mar 2022
DOACs, LMWH prevent VTE, but increase bleeding, in major noncardiac surgery
Use of direct oral anticoagulants (DOACs) and low molecular weight heparin (LMWH) appears to reduce venous thromboembolism (VTE) in major noncardiac surgery compared with no active treatment, a study has shown. However, it may also increase major bleeding to a similar extent.
DOACs, LMWH prevent VTE, but increase bleeding, in major noncardiac surgery
30 Mar 2022
SGLT2i better than DDP4i at preventing heart failure hospitalization, death in T2DM
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce hospitalization for heart failure (hHF) and all-cause death in type 2 diabetes mellitus (T2DM) patients without a history of cardiovascular disease, reports a new study.